Jia Fan

发表

Combined Hepatocellular Carcinoma and Cholangiocarcinoma: Clinical Features, Treatment Modalities, and Prognosis

Ying Zhou, S. Qiu, Jian Zhou, 2012, Annals of Surgical Oncology.

Risk Factors, Prognosis, and Management of Early and Late Intrahepatic Recurrence After Resection of Primary Clear Cell Carcinoma of the Liver

Q. Ye, L. Qin, S. Qiu, 2011, Annals of Surgical Oncology.

Intratumoral IL-17+ Cells and Neutrophils show Strong Prognostic Significance in Intrahepatic Cholangiocarcinoma

Q. Gao, Jian Zhou, Yinghong Shi, 2012, Annals of Surgical Oncology.

Phase I Clinical Trial of Oral Furtulon and Combined Hepatic Arterial Chemoembolization and Radiotherapy in Unresectable Primary Liver Cancers, Including Clinicopathologic Study

L. Qin, Zeng-chen Ma, Zhi-quan Wu, 2000, American journal of clinical oncology.

Effectiveness and safety of lenvatinib plus anti‐programmed death‐1 antibodies in patients with hepatocellular carcinoma: A real‐world cohort study

Jian Zhou, Chang-jun Tan, Jia Fan, 2023, Cancer medicine.

Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study

S. Qiu, Jian Zhou, Jian Sun, 2023, Signal Transduction and Targeted Therapy.

Integrative analyses identify CD73 as a prognostic biomarker and immunotherapeutic target in intrahepatic cholangiocarcinoma

S. Qiu, Jian Zhou, Jia Fan, 2023, World Journal of Surgical Oncology.

Interferon Regulatory Factor (IRF)-1 and IRF-2 are Associated with Prognosis and Tumor Invasion in HCC

S. Qiu, Q. Gao, Jian Zhou, 2012, Annals of Surgical Oncology.

Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapy

Jian Zhou, Sheng-xiang Rao, Jia Fan, 2023, Frontiers in Oncology.

Lenvatinib Induces Immunogenic Cell Death and Triggers Toll-Like Receptor-3/4 Ligands in Hepatocellular Carcinoma

S. Qiu, Jian Zhou, N. Ren, 2023, Journal of hepatocellular carcinoma.

Synthetic miR-26a mimics delivered by tumor exosomes repress hepatocellular carcinoma through downregulating lymphoid enhancer factor 1

Bo Hu, Wei-feng Liu, Jia Fan, 2023, Hepatology International.

Radiographic and α-fetoprotein response predict pathologic complete response to immunotherapy plus a TKI in hepatocellular carcinoma: a multicenter study

Haifeng Zhao, Jian Zhou, Yuan Ji, 2023, BMC Cancer.

The development and prospects of liver surgery

Zhao-You Tang, Jian Zhou, Chang-jun Tan, 2023, Clinical Surgical Oncology.

Tumor‐derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression

F. jia, Jia Fan, Jian Zhou, 2022, Hepatology.

Enhancing the anticancer immune response with the assistance of drug repurposing and delivery systems

Yanfeng Gao, Jia Fan, Xiaoming Zhang, 2023, Clinical and translational medicine.

Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study

Xiaozhong Chen, Ming-Yuan Chen, Jia Fan, 2023, EClinicalMedicine.

Association of BRAF Variants With Disease Characteristics, Prognosis, and Targeted Therapy Response in Intrahepatic Cholangiocarcinoma

Jia Fan, Jian Zhou, Zhi-qiang Hu, 2023, JAMA network open.

Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and multi-arm randomised, phase 1 trial

M. Shen, F. Zhu, Jia Fan, 2023, eBioMedicine.

Efficacy and safety of proxalutamide (GT0918) in severe or critically ill patients with COVID-19: study protocol for a prospective, open-label, single-arm, single-center exploratory trial

Min-jie Ju, Jia Fan, Yichen Jia, 2023, BMC Pharmacology and Toxicology.

An invasive zone in human liver cancer identified by Stereo-seq promotes hepatocyte–tumor cell crosstalk, local immunosuppression and tumor progression

Yao Li, Huanming Yang, Yuxiang Li, 2023, Cell Research.

Development of a deep pathomics score for predicting hepatocellular carcinoma recurrence after liver transplantation

G. Zhu, Jian Zhou, Meng-Xin Tian, 2023, Hepatology International.

A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights

Jian Zhou, Jia Fan, Qiang Gao, 2023, Hepatobiliary surgery and nutrition.

Dissecting the tumor ecosystem of liver cancers in the single-cell era

Jian Zhou, Jia Fan, Yunfan Sun, 2023, Hepatology communications.

Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective

Jia Fan, Jian Zhou, Jieyi Shi, 2022, Clinical and molecular hepatology.

Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology

H. Clevers, Pei Wang, S. Qiu, 2023, Science Translational Medicine.

Opportunities and challenges of liquid biopsy in liver cancer

Jia Fan, Jian-Wen Cheng, Xinchun Yang, 2023, Clinical Surgical Oncology.

Development of a miR-26 Companion Diagnostic Test for Adjuvant Interferon-alpha Therapy in Hepatocellular Carcinoma

Jason G. Jin, X. Wang, K. Wakasa, 2013, International journal of biological sciences.

Prognosis of spontaneously ruptured hepatocellular carcinoma: a propensity score matching study

Shenmin Zhang, Jian Zhou, Jia Fan, 2023, Journal of Cancer Research and Clinical Oncology.

Prognostic model for predicting outcome and guiding treatment decision for unresectable hepatocellular carcinoma treated with lenvatinib monotherapy or lenvatinib plus immunotherapy

Shenmin Zhang, Jian Zhou, Sheng-xiang Rao, 2023, Frontiers in Immunology.

The effect of antiviral therapy on patients with hepatitis B virus-related hepatocellular carcinoma after curative resection: a systematic review and meta-analysis

Jia Fan, Xin Zhang, Jian Wang, 2017, OncoTargets and therapy.

CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma.

Jia Fan, Jian Zhou, Yongsheng Xiao, 2024, Journal of hepatology.

Proteomic and metabolomic features in patients with HCC responding to lenvatinib and anti-PD1 therapy.

Jia-bin Cai, Jia Fan, Jian Zhou, 2024, Cell reports.

Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma.

Dongbing Liu, Huichuan Sun, Pin Wu, 2023, Cancer cell.

Correction: Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis

A. Ke, Jia Fan, Chao Gao, 2024, Molecular cancer.

MAIT cells confer resistance to Lenvatinib plus anti-PD1 antibodies in hepatocellular carcinoma through TNF-TNFRSF1B pathway.

S. Qiu, Jia Fan, Jian Zhou, 2023, Clinical immunology.

Neutrophil profiling illuminates anti-tumor antigen-presenting potency

Yingcheng Wu, Jia Fan, Jian Zhou, 2024, Cell.

Tacrolimus enhances the invasion potential of hepatocellular carcinoma cells and promotes lymphatic metastasis in a rat model of hepatocellular carcinoma: involvement of vascular endothelial growth factor-C.

Jia Fan, Jian Zhou, Z. Dai, 2011, Transplantation proceedings.

Early detection and prognosis evaluation for hepatocellular carcinoma by circulating tumour DNA methylation: A multicentre cohort study

Jia Fan, Jian-Wen Cheng, Zhixi Su, 2024, Clinical and translational medicine.